Germ-line BRCA1/2 testing recommended in ovarian cancer

June 19, 2012
Germ-Line <i>BRCA1/2</i> testing recommended in ovarian cancer
Due to the potential survival and treatment response implications of BRCA mutation status, it is recommended that germ-line BRCA1/2 testing be offered to all women diagnosed with nonmucinous ovarian carcinoma, regardless of family history, according to research published online June 18 in the Journal of Clinical Oncology.

(HealthDay) -- Due to the potential survival and treatment response implications of BRCA mutation status, it is recommended that germ-line BRCA1/2 testing be offered to all women diagnosed with nonmucinous ovarian carcinoma, regardless of family history, according to research published online June 18 in the Journal of Clinical Oncology.

To investigate the impact of germ-line BRCA1 and BRCA2 mutations in ovarian cancer, Kathryn Alsop, of the Peter MacCallum Cancer Centre in East Melbourne, Australia, and colleagues screened 1,001 women with nonmucinous ovarian carcinomas enrolled in a case-control study for germ-line point mutations and large deletions in BRCA1 and BRCA2 genes.

The researchers found that 14.1 percent of patients exhibited BRCA1/2 germ-line mutations. Of these, 16.6 percent had serous cancer and 44 percent reported no family history of either breast or ovarian cancer. Compared with women without germ-line mutations, patients with germ-line mutations had improved rates of progression-free and overall survival and tended to respond to platin and nonplatin-based regimens in the relapse setting. Somatic BRCA1/2 mutations were more likely to be found in mutation-negative patients who responded to multiple cycles of platin-based treatment.

"Our findings suggest changes in the guidelines for genetic testing of all invasive ovarian cancer patients, indicate that the measurement of BRCA status should be explicitly integrated into future clinical trial designs as a major stratification factor, and declare BRCA status is now ready to be included in the of women with ," the authors write.

Explore further: BRCA2 genetic mutation associated with improved survival, chemotherapy response in ovarian cancer

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

BRCA2 genetic mutation associated with improved survival, chemotherapy response in ovarian cancer

October 11, 2011
Among women with a certain type of high-grade ovarian cancer, having BRCA2 genetic mutations, but not BRCA1, was associated with improved overall survival and improved response to chemotherapy, compared to women with BRCA ...

Women with certain type of ovarian cancer and BRCA gene mutation have improved survival at 5 years

January 24, 2012
Among women with invasive epithelial ovarian cancer, patients having a germline (gene change in a reproductive cell that could be passed to offspring) mutation in the BRCA1 or BRCA2 genes was associated with improved 5-year ...

Gene inheritance patterns influence age of diagnosis in BRCA families

December 12, 2011
Women who inherit the cancer genes BRCA1 or BRCA2 from their paternal lineage may get a diagnosis a decade earlier than those women who carry the cancer genes from their mother and her ancestors, according to a new study ...

Recommended for you

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Scientists develop novel immunotherapy technology for prostate cancer

August 17, 2017
A study led by scientists at The Wistar Institute describes a novel immunotherapeutic strategy for the treatment of cancer based on the use of synthetic DNA to directly encode protective antibodies against a cancer specific ...

Outdoor light at night linked with increased breast cancer risk in women

August 17, 2017
Women who live in areas with higher levels of outdoor light at night may be at higher risk for breast cancer than those living in areas with lower levels, according to a large long-term study from Harvard T.H. Chan School ...

Toxic formaldehyde is produced inside our own cells, scientists discover

August 16, 2017
New research has revealed that some of the toxin formaldehyde in our bodies does not come from our environment - it is a by-product of an essential reaction inside our own cells. This could provide new targets for developing ...

Cell cycle-blocking drugs can shrink tumors by enlisting immune system in attack on cancer

August 16, 2017
In the brief time that drugs known as CDK4/6 inhibitors have been approved for the treatment of metastatic breast cancer, doctors have made a startling observation: in certain patients, the drugs—designed to halt cancer ...

Researchers find 'switch' that turns on immune cells' tumor-killing ability

August 16, 2017
Molecular biologists led by Leonid Pobezinsky and his wife and research collaborator Elena Pobezinskaya at the University of Massachusetts Amherst have published results that for the first time show how a microRNA molecule ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.